Gene therapy in cystic fibrosis

Translational Research

Volumn 161, Issue 4, 2013, Pages 255-264

  Prickett, Michelle ^a   Jain, Manu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ATALUREN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; MESSENGER RNA; MUTANT PROTEIN; PLACEBO;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; CYSTIC FIBROSIS; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; GENE MUTATION; GENE VECTOR; GENETIC DISORDER; HUMAN; NONHUMAN; NONVIRAL GENE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POTENTIAL DIFFERENCE; PRIORITY JOURNAL; REVIEW; VIRAL GENE THERAPY; WILD TYPE;

EID: 84875175557     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.12.001     Document Type: Review

References (77)

1. R. Busch On the history of cystic fibrosis Acta Universitatis Carolinae. Medica 36 1990 13 15
2. J. Alonso Y De Los Ruyzes De Fonteca Diez Previlegios para Mgeres Prenadas Alcala de Henares 212 1606
3. A.E. Garrod, and W.H. Hurtley Congenital Family Steatorrhea Q J Med 6 1912 242 258
4. D.H. Andersen Cystic Fibrosis of the pancreas and its relation to celiac disease Am J Dis Child 56 1938 344 399
5. D.H. Andersen, and R.G. Hodges Celiac syndrome; genetics of cystic fibrosis of the pancreas, with a consideration of etiology Am J Dis Child 72 1946 62 80
6. P.A. Di Sant'Agnese, R.C. Darling, G.A. Perera, and E. Shea Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease Pediatrics 12 1953 549 563
7. L.E. Gibson, and R.E. Cooke A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis Pediatrics 23 1959 545 549
8. R.C. Boucher, M.J. Stutts, M.R. Knowles, L. Cantley, and J.T. Gatzy Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation J Clin Invest 78 1986 1245 1252
9. M.R. Knowles, M.J. Stutts, A. Spock, N. Fischer, J.T. Gatzy, and R.C. Boucher Abnormal ion permeation through cystic fibrosis respiratory epithelium Science 221 1983 1067 1070
10. B. Kerem, J.M. Rommens, and J.A. Buchanan Identification of the cystic fibrosis gene: genetic analysis Science 245 1989 1073 1080
11. J.R. Riordan, J.M. Rommens, and B. Kerem Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA Science 245 1989 1066 1073
12. J.M. Rommens, M.C. Iannuzzi, and B. Kerem Identification of the cystic fibrosis gene: chromosome walking and jumping Science 245 1989 1059 1065
13. Cystic Fibrosis Mutation Database. Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto. Available at: http://www.genet.sickkids.on.ca; 1989. Accessed April 9, 2012.
14. J. Zielenski, and L.C. Tsui Cystic fibrosis: genotypic and phenotypic variations Ann Rev Genet 29 1995 777 807
15. M.J. Welsh, and A.E. Smith Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis Cell 73 1993 1251 1254
16. K. Varga, R.F. Goldstein, and A. Jurkuvenaite Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones Biochem J 410 2008 555 564
17. T.C. Hwang, F. Wang, I.C. Yang, and W.W. Reenstra Genistein potentiates wild-type and delta F508-CFTR channel activity Am J Physiol 273 3 Pt 1 1997 C988 C998
18. G. McLachlan, H. Davidson, and E. Holder Preclinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung Gene Ther 18 2011 996 1005
19. U. Griesenbach, and E.W. Alton Cystic fibrosis gene therapy: successes, failures and hopes for the future Expert Rev Respir Med 3 2009 363 371
20. U. Griesenbach, and E.W. Alton Current status and future directions of gene and cell therapy for cystic fibrosis BioDrugs 25 2011 77 88
21. U. Griesenbach, and E.W. Alton Progress in gene and cell therapy for cystic fibrosis lung disease Curr Pharmaceut Design 18 2012 642 662
22. U. Griesenbach, D.M. Geddes, and E.W. Alton Gene therapy progress and prospects: cystic fibrosis Gene Ther 13 2006 1061 1067
23. J.C. Davies, and E.W. Alton Gene therapy for cystic fibrosis Proc Am Thorac Soc 7 2010 408 414
24. N. Kalin, A. Claass, M. Sommer, E. Puchelle, and B. Tummler DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis J Clin Invest 103 1999 1379 1389
25. M. Wilschanski, A. Dupuis, and L. Ellis Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials Am J Respir Crit Care Med 174 2006 787 794
26. S.C. Hyde, K.W. Southern, and U. Gileadi Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis Gene Ther 7 2000 1156 1165
27. S. Worgall, P.L. Leopold, G. Wolff, B. Ferris, N. Van Roijen, and R.G. Crystal Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract Hum Gene Ther 8 1997 1675 1684
28. R.W. Walters, T. Grunst, J.M. Bergelson, R.W. Finberg, M.J. Welsh, and J. Zabner Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia J Biol Chem 274 1999 10219 10226
29. J. Zabner, L.A. Couture, R.J. Gregory, S.M. Graham, A.E. Smith, and M.J. Welsh Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis Cell 75 1993 207 216
30. R.G. Crystal, N.G. McElvaney, and M.A. Rosenfeld Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis Nat Genet 8 1994 42 51
31. M.R. Knowles, K.W. Hohneker, and Z. Zhou A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis N Engl J Med 333 1995 823 831
32. J.G. Hay, N.G. McElvaney, J. Herena, and R.G. Crystal Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector Hum Gene Ther 6 1995 1487 1496
33. J. Zabner, B.W. Ramsey, and D.P. Meeker Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis J Clin Invest 97 1996 1504 1511
34. G. Bellon, L. Michel-Calemard, and D. Thouvenot Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial Hum Gene Ther 8 1997 15 25
35. B.G. Harvey, P.L. Leopold, and N.R. Hackett Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus J Clin Invest 104 1999 1245 1255
36. J.B. Zuckerman, C.B. Robinson, and K.S. McCoy A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis Hum Gene Ther 10 1999 2973 2985
37. M.A. Perricone, J.E. Morris, and K. Pavelka Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium Hum Gene Ther 12 2001 1383 1394
38. P.M. Joseph, B.P. O'Sullivan, and A. Lapey Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications Hum Gene Ther 12 2001 1369 1382
39. J.A. Wagner, A.H. Messner, and M.L. Moran Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus Laryngoscope 109 2 Pt 1 1999 266 274
40. M.L. Aitken, R.B. Moss, and D.A. Waltz A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease Hum Gene Ther 12 2001 1907 1916
41. J.A. Wagner, I.B. Nepomuceno, and A.H. Messner A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies Hum Gene Ther 13 2002 1349 1359
42. T.R. Flotte, P.L. Zeitlin, and T.C. Reynolds Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study Hum Gene Ther 14 2003 1079 1088
43. R.B. Moss, D. Rodman, and L.T. Spencer Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial Chest 125 2004 509 521
44. R.B. Moss, C. Milla, and J. Colombo Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial Hum Gene Ther 18 2007 726 732
45. S.G. Keswani, S. Balaji, and L. Le Pseudotyped AAV vector-mediated gene transfer in a human fetal trachea xenograft model: implications for in utero gene therapy for cystic fibrosis PLoS One 7 2012 e43633
46. F. Mingozzi, and K.A. High Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges Nat Rev Genet 12 2011 341 355
47. R. Kondo, M.A. Feitelson, and D.S. Strayer Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent Gene Ther 5 1998 575 582
48. U. Griesenbach, G. McLachlan, and T. Owaki Validation of recombinant Sendai virus in a non-natural host model Gene Ther 18 2011 182 188
49. P. Cmielewski, D.S. Anson, and D.W. Parsons Lysophosphatidylcholine as an adjuvant for lentiviral vector mediated gene transfer to airway epithelium: effect of acyl chain length Respir Res 11 2010 84
50. K.L. Kremer, K.R. Dunning, D.W. Parsons, and D.S. Anson Gene delivery to airway epithelial cells in vivo: a direct comparison of apical and basolateral transduction strategies using pseudotyped lentivirus vectors J Gene Med 9 2007 362 368
51. A.G. Stocker, K.L. Kremer, R. Koldej, D.S. Miller, D.S. Anson, and D.W. Parsons Single-dose lentiviral gene transfer for lifetime airway gene expression J Gene Med 11 2009 861 867
52. K. Mitomo, U. Griesenbach, and M. Inoue Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes Mol Ther 18 2010 1173 1182
53. U. Griesenbach, M. Inoue, and C. Meng Assessment of F/HN-Pseudotyped Lentivirus as a Clinically Relevant Vector for Lung Gene Therapy Am J Respir Crit Care Med 186 9 2012 846 856
54. M. Conese Cystic fibrosis and the innate immune system: therapeutic implications Endocrine Metab Immune Disord Drug Targets 11 2011 8 22
55. F.E. Ruiz, J.P. Clancy, and M.A. Perricone A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis Hum Gene Ther 12 2001 751 761
56. J.C. Davies, G. Davies, and D. Gill Safety and Expression of a Single Dose of Lipid-Mediated CFTR Gene Therapy to the Upper and Lower Airways of Patients with CF Pediatr Pulmonol 2011 46(Suppl)46:S34
57. M. Conese, F. Ascenzioni, and A.C. Boyd Gene and cell therapy for cystic fibrosis: from bench to bedside J Cyst Fibros 10 Suppl 2 2011 S114 S128
58. M.P. Anderson, R.J. Gregory, and S. Thompson Demonstration that CFTR is a chloride channel by alteration of its anion selectivity Science 253 1991 202 205
59. L. Tang, M. Fatehi, and P. Linsdell Mechanism of direct bicarbonate transport by the CFTR anion channel J Cyst Fibros 8 2009 115 121
60. P. Moskwa, D. Lorentzen, and K.J. Excoffon A novel host defense system of airways is defective in cystic fibrosis Am J Respir Crit Care Med 175 2007 174 183
61. S.H. Donaldson, and R.C. Boucher Sodium channels and cystic fibrosis Chest 132 2007 1631 1636
62. S.M. Rowe, S. Miller, and E.J. Sorscher Cystic fibrosis N Engl J Med 352 2005 1992 2001
63. F. Van Goor, S. Hadida, and P.D. Grootenhuis Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 Proc Natl Acad Sci U S A 106 2009 18825 18830
64. I. Sermet-Gaudelus, K.D. Boeck, and G.J. Casimir Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis Am J Respir Crit Care Med 182 2010 1262 1272
65. M. Wilschanski, Y. Yahav, and Y. Yaacov Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations N Engl J Med 349 2003 1433 1441
66. M. Howard, R.A. Frizzell, and D.M. Bedwell Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations Nat Med 2 1996 467 469
67. F.J. Accurso, S.M. Rowe, and J.P. Clancy Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation N Engl J Med 363 2010 1991 2003
68. B.W. Ramsey, J. Davies, and N.G. McElvaney A CFTR potentiator in patients with cystic fibrosis and the G551D mutation N Engl J Med 365 2011 1663 1672
69. J.C. Davies, H. Sheridan, P. Lee, T. Song, A. Stone, and F. Ratjen Lung Clearance Index to Evaluate the Effect of Ivacaftor on Lung Function in Subjects with CF who have the G551D-CFTR Mutation and Mild Lung Disease Pediatr Pulmonol 35 Suppl 35 2012 A249
70. H. Yu, B. Burton, and C.J. Huang Ivacaftor potentiation of multiple CFTR channels with gating mutations J Cyst Fibros 11 2012 237 245
71. S.M. Rowe, and J.P. Clancy Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development BioDrugs 23 2009 165 174
72. E. Kerem, S. Hirawat, and S. Armoni Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial Lancet 372 2008 719 727
73. J.P. Clancy, M.W. Konstan, S.M. Rowe, F. Accurso, P. Zeitlin, and S. Hirawat A phase II study of PTC124 in CF patients harboring premature stop mutations Pediatr Pulmonol 41 Suppl 41 2006 A269
74. S. Rowe, I. Sermet-Gaudelus, and M.W. Konstan Results of the Phase 3 Study of Ataluren in Nonsense Mutation Cystic Fibrosis (NMCF) Pediatr Pulmonol 35 Suppl 35 2012 A193
75. J.P. Clancy, S.M. Rowe, and F.J. Accurso Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation Thorax 67 2012 12 18
76. F. Van Goor, S. Hadida, and P.D. Grootenhuis Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 Proc Natl Acad Sci U S A 108 2011 18843 18848
77. M.P. Boyle, S. Bell, and M.W. Konstan The investigational CFTR corrector VX-809 (Lumacaftor) co-administered with the oral potentiator Ivacaftor improved CFTR and lung function in F508Del homozygous patients: phase II study results Pediatr Pulmonol 35 Suppl 35 2012 A260